NF2, in contrast, is almost entirely a disorder of tumor form a t i~n .~
The only common nontumor manifestation is cataract? Tumors include schwannomas of cranial and peripheral nerves, meningiomas, ependymomas, and gliomas. Bilateral deafness is common, and facial paralysis is also a frequent complication. This, too, is a progressive disorder and is commonly associated with significant neurological disability. Major morbidity associated with NF2 is listed in Table 2 .
PATHOGENESIS OF NF1 AND NF2
Virtually all of the knowledge about the pathogenesis of NF1 and NF2 is derived from studies performed since the genes were cloned. The NF1 gene is located on chromosome 17 and encodes a 2818 amino acid protein called "ne~rofibromin."~~'~ The NF2 gene is located on chromosome 22 and encodes a protein referred to as "merlin" or "s~hwannomin."'~~'~ The fundamental pathogenetic mechanism underlying tumors in both disorders is believed to be via a tumor suppressor mechanism (figure 1). This Table 1 Major complications associated with neurofibromatosis type 1 
System Complication
Central nervous system Optic glioma; astrocytoma; learning disability; cord compression Table 2 Major sources of morbidity associated with neurofibromatosis type 2
Central nervous system Vestibular schwannoma; other schwannomas; glioma; ependymoma; meningioma is very well supported for NF2, where tumors in patients tend to show loss of heterozygosity (LOH) for markers on chromosome 22.15,16 For NF1, LOH involving the NF1 region of chromosome 17 has been seen in malignant tumors and some benign neur~fibrornas.'~-'~ Neurofibromas contain multiple cell types, so cellular heterogeneity may account for some of the difficulty in detecting LOH. It remains possible that heterozygous NF1 mutation itself accounts for some phenotypic effects. Most NF1 germline mutations lead to premature termination of translation,2O so haploinsufficiency rather than dominant negative effects would be the postulated mechanism. This may be a particularly attractive hypothesis for the nontumor manifestations, such as learning disability. The NF1 gene includes a domain with GTPase activating protein (GAP) f u r~c t i o n .~~-~~ This GAP domain is functional and regulates GTPase activity for p21RAS. The NF1 protein binds t u b~l i n ,~~ but the function of areas of the protein outside the GAP domain is unknown. Current pathogenetic hypotheses therefore focus on the regulation of RAS (Figure 2 ). GAP proteins regulate RAS by stimulating the intrinsic GTPase in RAS to convert the active RAS-GTP form to the inactive RAS-GDP form. It is hypothesized that loss of neurofibromin leads to inability to inactivate RAS-GTP, leading to high levels of expression and consequent tumor formation. High levels of RAS-GTP indeed Invited Review/CME Article Fig. 2 Function of NF1 gene product in regulation of RAS. A ligand binds a receptor on the cell surface, which leads to activation of tyrosine kinase. Grb-2 binds with phosphorylated proteins and activates SOS (son of sevenless), whlch leads to activation of RAS through binding to GTP. Activated RAS binds to RAF-1, which activates MEK, leading to activation of MAP kinase (MAPK). MAPK then transduces a signal to the nucleus, leading to transcription of specific proteins. The NFl gene product is a GTPase activating protein, which stimulates intrinsic RAS GTPase, leading to inactivation of RAS by conversion of GTP to GDP.
have been found both in malignant and non-malignant NF1 tumors. 25 The exact mechanism whereby failure to inactivate RAS leads to abnormal behavior of nerve sheath cells is unknown.
The NF2 gene product is a cytoskeletal protein, homologous to members of the protein 4.1 family, including ezrin, radixin, and moeisin (figure 3).13 It co-localizes in the cell with a~t i n~~ and may be involved in the membrane changes that occur with cellular responses to extrinsic signals. The mechanism whereby loss of function of the NF2 product leads to tumor formation is unknown, however.
OUTCOMES MEASUREMENT IN CLINICAL TRIALS
Both NF1 and NF2 pose special challenges in definition and measurement of outcomes that will need to be faced before clinical trials can be undertaken. Growth of tumors can be very slow May/June s99 Vol. 1 . No. 4 and unpredictable, and in some instances can remit spontaneously. This will make it important to have data on natural history, lest spontaneous cessation of tumor growth be mistakenly attributed to the effects of a drug being tested. The tumors may be large and irregularly shaped, especially for plexiform neurofibromas in NF1. This makes it difficult to accurately measure tumor size, which will be necessary in documenting the efficacy of treatment.
These problems are currently being addressed in a pair of natural history studies funded by the U.S. Army Medical Research Command. Both are using volumetric MRI to study the growth of either plexiform neurofibromas in NF1 or vestibular schwannomas in NF2. It is hoped that these studies will establish the utility of this imaging mode in measuring change in these tumors and will generate a body of normative data on patterns of tumor growth.
Another challenge is the fact that both disorders tend to be lifelong and progressive. Any therapy that does not permanently ablate all tumors and potential tumors will need to be continued over a long period of time, perhaps a lifetime. This severely limits the degree of acceptable toxicity for potential drugs used for treatment. It is also unclear whether treatments will be cytostatic or cytotoxic. If the former is the case, it is likely that treatments will be more effective at preventing tumor growth than at reversing already established tumor bulk. This may require treatment of young children before onset of severe symptoms, which again requires a low level of toxicity and knowledge of the natural history to predict which patients will develop large or numerous tumors.
Because NF1 may become symptomatically progressive in pediatric patients and adults, phase 1 studies, which determine the pharmacodynamics and pharmacokinetics of candidate agents, must be performed in both adults and children. The FDA requires pediatric phase 1 testing for any agent that will be used in children. Formulation is important in pediatric trials. Treatments that require frequent intravenous dosing, continuous intravenous infusion, or even multiple daily oral dosing are cumbersome for adults and may be prohibitively cumbersome or disruptive for children. Of course a truly effective and safe agent would justify significant inconvenience, but in choosing candidate agents for therapeutic trials in children, the impact on quality of life must be an important consideration.
Rational drug development for the treatment of NF1 and NF2 is hampered by the lack of representative and easily manipulated animal models. Although knockout mice homozygous for deletion of the NF1 gene have allowed study of the developmental sequelae of NF1 mutation, they are not good models for the study of treatment of NF1 related tumors.27 NF1 knockouts do not develop neurofibromas or astrocytomas with short latency or useful frequency. Although an animal model of NF2 has been developed and these animals develop tumors of the cranial nerves, which resemble human schwannomas, these tumors do not develop in a high percentage of animals.28 In addition, tumor latency is too long for drug testing. Unfortunately, the lack of an animal model makes it difficult to prioritize drugs for entry into clinical trial.
Clinical Trials for NF1

Malignant Tumors
Although a feared complication, malignancy is rare in patients with NF1. Acute myelogenous leukemia (ATv~L)'~ and malignant peripheral nerve sheath tumors (MPNST) are the most common malignancies. Patients with AML and NF1 frequently have chromosomal abnormalities associated with poor response to chemotherapy, such as monosomy 7.30 MPNST usually arise within preexisting plexiform neurofibromas, but may arise de n o~o .~' ,~~ MPNST arise as localized tumors, often causing exacerbation of pain, preexisting neurologic deficit, or rapid growth in size of a known plexiform neurofibroma. MPNST behave similarly to other soft tissue sarcomas, and systemic metastasis is often the cause of death.
When a locally resectable MPNST is removed, current adjuvant chemotherapeutic regimens have little impact on the risk of recurrence, similar to other soft tissue sarcomas.33 Somatic gene transfer strategies and immunomodulators may have a role in management of MPNST. This problem may be addressed by using a tumor vaccine strategy, analogous to those currently in clinical trial for patients with melanoma or colon cancer. 34 Cytokine based cellular vaccines, using autologous tumor cells and vectors transferring various immunostimulatory cytokines are one approach; these protocols require culturing autologous tumor cells for gene transfer and then subcutaneous injection after irradiation of the tumor cells. Alternatively, killed tumor cell vaccines administered with adjuvant may be another approach. 35 An adjuvant-killed tumor cell vaccine protocol for patients with locally resected soft tissue sarcomas is planned at the University of Pittsburgh, Pittsburgh Cancer Institute.
Neurofibrornas
The role of NF1 in the regulation of RAS makes this pathway a prime target for therapeutic manipulation. For RAS mediated signal transduction to propagate, the activated RAS molecule and linking proteins must be translocated to the inner surface of the cytoplasmic membrane and fixed there by attachment of a long chain fatty acid, farnesyl (Figure 4) , through the action of enzymes referred to as farnesyl protein transfera~es.~~ Three pharmaceutical companies have farnesyl transferase inhibitors (FTI) in development as anti-cancer drugs. A phase 1 study of one FTI is currently underway in the Pediatric Branch of the National Cancer Institute for children with progressive PN. This drug is administered orally. The investigators anticipate that the maximum tolerated dose for the phase 2 trial of potential efficacy will be completed within the next 6 months. Although the enzymatic pathway for regenerating retinal photoreceptor pigment also involves a farnesylation step, no visual toxicity has been observed to date in the phase 1 trial. If successful, the FTI will represent one of the first applications of molecularly targeted therapy to the treatment of human neoplasms. Because recent observations implicate the RAS signaling pathway in both NF1 related and sporadic astrocytomas, FTI may have important applications beyond the treatment of PN. 37 A number of agents that have been tested for other cancer treatment indications may be applied to the treatment of Genetics IN W c i n e plexiform neurofibromas. Because these agents already have phase 1 safety and dosing data available, efficacy studies are straightforward. In considering the prioritization of testing such agents, preclinical efficacy in animal or in vitro models, toxicity profile, and convenience of administration are all relevant concerns.
Differentiation inducers are drugs that inhibit tumor cell proliferation and induce phenotypic changes associated with a mature neuronal or glial cell. Clinically relevant differentiation inducers include the retinoids, polar-nonpolar compounds, and short chain aromatic fatty acids. The prototypic differentiation inducers are the retinoids, a family of molecules related to vitamin A, whose cellular expression is normally developmentally regulated.
AU trans retinoic acid (ATRA) has become first line therapy for patients with acute promyelocytic leukemia (APL) and has also been tested in phase 2 studies in patients with recurrent malignant astr~cytoma.~~ Treatment with ATRA increases time to progression in patients with recurrent malignant astrocytoma.39 Retinoids act though interaction with a multimember family of receptor^.^' Selectivity of response is determined in part by preferential affinity for different subclasses of receptors, which dimerize after ligand binding and translocate to the nucleus of the cell. Various heterodimer or homodimer complexes then react with varying affinity to different retinoic acid binding domains in nuclear DNA; the retinoic acid binding domains are transcriptional regulators for a variety of genes involved in regulation of cell proliferation or cellular phenotype. A related retinoid, 13-cis retinoic acid, has similar effects in patients with recurrent m d gnant a~trocytomas~~ and 9-cis retinoic acid has been tested in patients with lung cancer in phase 1 studies. 42 Ideally, a differentiation inducer should produce terminal differentiation and loss of proliferative potential or induce apoptosis. When a differentiation inducer does neither, continued administration may be required to maintain the antiproliferative effect. In APL, treatment with ATRA does induce terminal differentiation, but in treatment of neuroectodermal tumors, treatment effect is transient. In viho studies of astrocytoma and medulloblastoma derived cell lines demonstrated loss of antiproliferative effects after washout of ATRA. 43 In treatment of PN, continued administration would probably be required. The regimen used in treatment of anaplastic astrocytoma is 50 mglm2 bid for 21 days followed by a 7-day rest to complete one cycle. There is minimal myelosuppression with retinoid treatment. The most common toxicity is cheilosis; headache is also frequent and may be mistaken for tumor related increased intracranial pressure. This syndrome is similar to the pseudotumor cerebri seen in patients taking supraphysiologic doses of vitamin A. A l l the retinoids are powerful teratogens. These drugs must be tested with extreme care in women of childbearing age. Females participating in such trials should have a pregnancy test documented before study entry and use effective contraception during treatment.
The short chain aromatic fatty acids phenylacetate (PA) and phenylbutyrate (PBA) induce differentiation and inhibit prohferation of a wide range of neoplastic cell lines in vitro, including astrocytoma, neuroblastoma, and medullobla~toma.~~ PA and PBA have been tested in phase 1 trials of mdgnant glioma, and PBA has a well-established safety record, being used to treat neonatal hyperammonemia associated with urea cycle abnormalities. PA must be given as a continuous intravenous infusion because of its short half-life in serum; PBA is available in both intravenous and oral formulations. In most in viho systems, PBA is more potent on a molar basis than PA, but PBA is rapidly metabolized to PA in serum. Although the results of a phase 2 study of phenylacetate for patients with recurrent malignant astrocytoma are disappointing, a more intense dosing schedule is currently being evaluated.45 Phenylbutyrate, which is more potent in vitro on a molar basis than phenyla~etate,~~ warrants further evaluation in the treatment of malignant glioma. A phase 1 trial of PBA for patients with progressive plexiform neurofibroma has begun at the Pediatric Branch of the NCI.
In a number of in vitro systems, including human leukemia derived cell lines and colon cancer cell lines, sequential treatment with a cytotoxic chemotherapeutic drug and then a differentiation inducer increases the potency of the differentiation inducer. A phase 1 trial of 5-flurouracil(5-FU) followed by intravenous phenylbutyrate is underway at Mt. Sinai Medical Center, New York, NY for patients with metastatic colon cancer. Although cytoreductive drugs, especially alkylating agents, are contraindicated in patients with NFl, combination strategies might be considered for NF1 associated astrocytomas. Because carboplatin and vincristine or etoposide are commonly used for progressive pediatric low-grade astro~ytomas,4~ combination therapy with carboplatin followed by PBA may be a reasonable approach to test in phase 1 trials. Antiangiogenesis agents are being tested in animal models of a variety of high grade neoplasms, includmg malignant gli0rnas.4~ These drugs interfere with one or more of the signaling molecules, which induce new blood vessel formation in the vicinity of growing tumors. A number of agents are in preclinical development, including angiostatin and endostatin. Thalidomide acts as an antiangiogenesis agent in animal models of some tumor types, including malignant glioma, and a phase 1 trial of thalidomide for patients with progressive plexiform neurofibroma is accruing patients in a Childrens' Cancer Study Group Thalidomide has recently become commercially available for a nononcologic indication; the usual dose limiting toxicity is sedation. Of course, the drug must be used with extreme caution in women of childbearing age. Antiangiogenesis agents cannot be evaluated in in vitro tumor cell models, since the phenomena of tumor induced angiogenesis can only be studied in animal models of growing solid tumors. The role of angiogenesis in progression PN is probably minimal, because these slow growing neoplasms do not demonstrate significant neovascularity. In patients with MPNST, antiangiogenesis agents are conceptually applicable. Since the statin drugs are difficult synthetic challenges, these drugs will be in short supply for clinical trials and will probably be tested in patients with more common refractory malignancies such as lung or breast cancer. Other agents are being developed that inhibit signal transduction through the vascular endothelial growth factor pathway. Both small molecule and monoclonal antibody based therapies are being readied for phase 1 clinical testing in solid tumors; again these agents are intriguing candidates for treatment of MPNST and perhaps progressive PN.
Treatment Trials for NF2
Although limited insight into the molecular pathophysiology of NF2 related neoplasia precludes rational targeted drug design, several drugs that have been developed to treat sporadic meningiomas may warrant clinical evaluation in NF2 related neoplasms. Indeed, the occurrence of NF2 mutations in a significant fraction of sporadic meningiomas suggests that therapies that affect NF2 related neoplasms might have more general appli~ation.~~ Several agents have been tested in sporadic meningiomas. Hydroxyurea is a cytoreductive drug used for many years in the treatment of adult chronic myelogenous leukemia, so that the toxicity profile is well established in adults. Hydroxyurea was reported to produce radiological responses in patients with unresectable meningiomas in a small clinical series reported from Germany.50~51 Hydroxyurea induces apoptosis in meningioma derived cell lines, leading to the hope that the drug would not require protracted administration, but studies in the United States and Canada suggest that the most frequent treatment effect is stable disease. Most patients have been treated with hydroxyurea for 1 to 2 years at most; the efficacy and toxicity of more protracted administration is unstudied, although experience with CML suggests that toxicity other than myelosuppression should be minimal in adults.52
Expression of platelet derived growth factor receptor (PDGFr) is common in sporadic meningiomas, and PDGFr antagonists may inhibit proliferation of meningioma cells. SU-101, a drug that inhibits autophosphorylation of PDGFr, is currently in phase 2 trial for patients with recurrent malignant astrocytoma; this drug has minimal myelotoxicity and is an attractive agent for clinical trial in NF2 related rneningi~mas.~~ The drug is administered by intravenous infusion, and the long half-life of the active metabolite in serum allows administration at 14-day intervals. A substantial percentage of sporadic meningiomas express estrogen receptors, and estrogen antagonists have demonstrated efficacy in phase 2 trials in patients with unresedable meningiomas. Tamoxifen, used in doses somewhat higher than for breast cancer treatment or prophylaxis, induced radiological regression or stabilized meningiomas in a small phase 2 Raloxifene, a new estrogen antagonist is being evaluated as an agent that will decrease the risk of breast cancer in women at high risk. Raloxifene has been tested in a large study of patients at risk for osteoporosis and appears to have a favorable toxicity profile. This drug warrants study in the treatment of meningiomas. There may be an increased risk of venous thromboembolism associated with raloxifene, as with tamoxifen, and the anti-estrogenic effects w i l l be problematic for premenopausal women.
Immunomodulatory cytokines may inhibit meningioma growth. Preliminary data suggest that alpha-interferon has a direct antiproliferative effect on meningioma cells in culture, and some radiographic responses have been reported in patients.56 Interferon-alpha is administered by subcutaneous injection and the most common side effects are local inflammation at the injection site and a "flu" like syndrome. Sequential combination therapy with interferons and differentiation inducers have demonstrated synergistic activity in other tumor cell systems in vitro; further laboratory investigation is needed to determine whether this strategy is worthwhile for patients with meningiomas.
Since hydroxyurea is established as a safe but incompletely effective therapy for meningiomas, combination therapy with a differentiation inducer is an attractive strategy.57 This regimen should be tested in vitro for synergistic activity and if found to be active, could be moved into clinical trial for patients with NF2 related and sporadic meningiomas.
The clinical validation of the use of locally implantable wafers that release chemotherapeutic agents, for which the paradigm is the use of Gliodel wafers in patients with recurrent malignant g l i~m a ,~~ suggests a role for such preparations in the treatment of skull base or posterior fossa meningiomas. Although BCNU is probably not the optimal drug for local treatment of meningiomas, the same wafer technology can be applied to other hydrophilic chemotherapeutic agents.
CONCLUSION
Investigators and patients both hope that the new millennium will see the development of effective treatments to benefit patients with NF1 and NF2 related neoplasms. As we begin to study possible therapies, we must be careful to design studies so that we can learn kom each attempt and r e h e the therapeutic approaches as efficiently as possible.
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